Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,902 matching trials from the live ClinicalTrials.gov search.
Conditions
Mucositis, Nephrotoxicity, Ototoxicity
Interventions
Tempol, Placebo Solution
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
La Jolla, California • Merced, California • San Francisco, California + 4 more
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

NCT01533636
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy Subjects
Interventions
Sativex® (Treatment A), Sativex® and fluconazole concomitantly (Treatment B)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Anaheim, California
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 15 more
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 110 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
LY3437943, Midazolam, Warfarin, Caffeine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Conditions
Systemic Lupus Erythematosus, Healthy Participants
Interventions
BMS-986165, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Acute Pain, Burns, Adverse Drug Event, Respiratory Depression, Nausea and Vomiting, Postoperative
Interventions
Oliceridine, Historical opioid use
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Perimenopause, Menopause
Interventions
Navigating Menopause with a Mindfulness-Based Group Medical Visit
Other
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 5 more
Conditions
Drug Use, HIV, Hepatitis C
Interventions
Brief motivational intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Drug-drug Interaction
Interventions
Tucatinib, Metformin, Iohexol
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans

NCT02901275
Conditions
Pain, Cannabis, Opioid Use, Unspecified
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
Interventions
CORA- Device:smartphones"
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts